$STLN News

Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call

Starling Oncology (STLN) Stock Gets Fair Value Boost On Capitated Revenue And Nexus Views

Needham Maintains Buy on Starling Oncology, Raises Price Target to $9

Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation

Starling Oncology: Improving Cash Flow And Gross Profit Fuel A Re-Rating

Starling Oncology to Participate in Wells Fargo Healthcare Conference

Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale

Oncology Institute Q2 Earnings Call Highlights

Starling Oncology shares are trading higher after the company reported a year-over-year decrease in Q2 loss per share and increase in sales results.

Starling Oncology Q2 EPS $(0.08) Up From $(0.15) YoY, Sales $161.282M Up From $119.802M YoY

Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript

Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

Is Oncology Institute (TOI) One of the Best Future Stocks to Buy Under $10?

BTIG Maintains Buy on Oncology Institute, Raises Price Target to $9

The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity

Why Oncology Institute’s (TOI) Analyst Upgrades Put Its Community Cancer Care Growth Story in Focus

Lake Street Initiates Coverage On Oncology Institute with Buy Rating, Announces Price Target of $10

The Oncology Institute (TOI) Soars 5.3%: Is Further Upside Left in the Stock?

Needham Maintains Buy on Oncology Institute, Raises Price Target to $7

How Much Upside is Left in The Oncology Institute (TOI)? Wall Street Analysts Think 38.07%